Category Archives: 3922 – lorlatinib by Pfizer

Impact of EML4-ALK Variants on resistance

Posted on June 15, 2018 by admin

As of April 20, 2018 Study of 2 groups of patients. Group A = 129 patients, Group B = 577 patients. The most frequent variants were Variant 1 (43%) and Variant 3 (40%). “ALK resistance mutations were significantly more common … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment

Phase 1 & 2 full results for Lorlatinib

Posted on June 15, 2018 by admin

As of Oct. 16, 2017 Pfizer presented a Press release associated with a presentation at IASLC on Phase 2 results for 275 patients. All following are for ALK+ patients except where Ros1 is indicated Treatment Naive:  ORR 90%; IC-ORR 75% Prior … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, Brain metastases, Lung cancer, Potential Treatments, Research, Side Effects | Leave a comment

Great page with very high quality info on AlK & AlK inhibitors

Posted on June 16, 2017 by admin

Below is a link to a page that provides comprehensive regularly updated info written by two ALK research oncologists Dr. Alice Shaw and Ben Solomon, Phd (then edited by three people). It is written for an audience of doctors and … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments | Leave a comment

Lorlatinib granted breakthrough therapy status

Posted on June 6, 2017 by admin

On April 27, 2017, the FDA granted Pfizer Breakthrough Status on lorlatinib for patients previously treated with one or more ALK inhibitors. So you don’t have to take Crizotinib first, any of the other 3 will do. Also a Phase … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, Brain metastases, Lung cancer, Potential Treatments, Research | Leave a comment

Outcomes for ALK+ patients

Posted on May 22, 2016 by admin

Abstract e20550 is from Spain and involves 49 patients. Patients took 6 different ALK inhibitors. The abstract concluded “ALK+ patients who received targeted agents have prolonged survival despite brain metastases…. ALK inhibitors improve intracranial response rate and survival.”

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research | Leave a comment

Lorlatinib abstract

Posted on May 19, 2016 by admin

Abstract 9009 is a phase 1 dose escalation trial (dose levels ranged from 10-200 mg and the Recomended phas 2 dose was 100 mg once daily). There were 54 patients as of November 30, 2015. 41 are ALK positive and … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, Brain metastases, Lung cancer, Potential Treatments, Research, Resistance to treatment, Side Effects | Leave a comment

Upcoming ASCO abstracts

Posted on May 18, 2016 by admin

There are 14 abstracts for the upcoming ASCO that have ALK in the title. But only 6 look like they are likely to be broadly applicable to people on this board. I will be posting summaries over the next week … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer | Leave a comment

Article on latest develpments

Posted on March 26, 2016 by admin

In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, AP26113 - brigatinib from Ariad, ASP3026 from Astellas, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery | Leave a comment

Article by Dr. Shaw

Posted on February 20, 2016 by admin

Dr. Shaw discusses the recent approval of Alectinib and the treatment implications now that there are 3 ALK inhibitors approved by the FDA. http://www.ascopost.com/issues/january-25-2016/the-evolving-treatment-landscape-of-alk-positive-nsclc/

Posted in 3922 - lorlatinib by Pfizer, alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, ceritinib - Zykadia from Novartis, crizotinib - Xalkori from Pfizer, Imunotherapies, Lung cancer, Potential Treatments, Research | Leave a comment

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

Posted on January 12, 2016 by admin

Patients taking Pfizer’s Lorlatinib (after developing resistance to Crizotinib) can develop the L1198F mutation. The L1198F mutation causes the cancer cells that were previously resistant to Crizotinib to become sensitive to Crizotinib again. Essentially the two drugs can require mutually … Continue reading →

Posted in 3922 - lorlatinib by Pfizer, Brain metastases, crizotinib - Xalkori from Pfizer, Lung cancer, Potential Treatments, Research, Resistance to treatment | Leave a comment